Plas E, Riedl C R, Pflüger H
Department of Urology and LBI for Urology and Andrology, Lainz Hospital, Vienna, Austria.
Cancer. 1998 Dec 15;83(12):2437-46. doi: 10.1002/(sici)1097-0142(19981215)83:12<2437::aid-cncr6>3.0.co;2-g.
Only 73 cases of malignant mesothelioma of the tunica vaginalis testis have been reported in the last 30 years. Although these tumors were most often seen in patients between ages 55 and 75 years, 10% of the patients were younger than 25 years. Because prognostic parameters have not yet been reported, the authors present another case of a male age 14 years and a review of the available literature, which they conducted to determine prognostic parameters.
The medical literature about malignant mesothelioma of the tunica vaginalis testis was reviewed. For the determination of prognostic parameters, a univariate and multivariate Cox regression model was used to assess the relevance of the patient's age, history of asbestos exposure, tumor histology, primary therapeutic approach, and presence of metastatic disease to survival.
Previous exposure to asbestos or asbestos-containing materials must be considered a risk factor for the development of malignant mesothelioma. The major difficulty in managing patients with malignant mesothelioma of the tunica vaginalis testis was determining an accurate preoperative diagnosis, which was reported in only two cases. Due to the lack of characteristic symptoms, 97.3% of the cases were diagnosed intraoperatively. Of patients who underwent local resection of the hydrocele wall, 35.7% experienced local tumor recurrence, as compared with 10.5% after scrotal orchiectomy and 11.5% after inguinal orchiectomy. Therefore, radical orchiectomy should be the first-line therapy. The median survival of the patients was 23 months, which decreased to 14 months in cases of recurrence. The overall recurrence rate (local and disseminated) was 52.5%. More than 60% of recurrences developed within the first 2 years of the follow-up. In some cases of disseminated mesothelioma, adjuvant chemotherapy or radiotherapy was given. Although reports on adjuvant treatments were limited, radiotherapy appeared to be more effective than chemotherapy. However, 37.9% died of disease progression. Assessment of prognostic parameters revealed a significant correlation of patient's age with survival (P < 0.01), with a better outcome for younger patients and a worse disease course for patients with primary disseminated disease (P < 0.05) in univariate analysis. A multivariate Cox regression model of prognostic parameters concerning survival did not yield statistically significant results.
Malignant mesotheliomas of the tunica vaginalis testis rarely occur, but the possibility should be considered for all age groups. Univariate analysis determined that a patient's age and the presence of primary disseminated disease were prognostic parameters related to survival. Due to the invasive potential of this disease and the risk of tumor recurrence, radical orchiectomy and close follow-up are strongly recommended.
在过去30年中,仅报道了73例睾丸鞘膜恶性间皮瘤病例。虽然这些肿瘤最常见于55至75岁的患者,但10%的患者年龄小于25岁。由于尚未报道预后参数,作者报告了另一例14岁男性病例,并对现有文献进行了回顾,以确定预后参数。
回顾了关于睾丸鞘膜恶性间皮瘤的医学文献。为了确定预后参数,使用单变量和多变量Cox回归模型来评估患者年龄、石棉暴露史、肿瘤组织学、主要治疗方法以及转移性疾病的存在与生存的相关性。
既往接触石棉或含石棉材料必须被视为发生恶性间皮瘤的危险因素。治疗睾丸鞘膜恶性间皮瘤患者的主要困难在于术前准确诊断,仅两例报道了术前准确诊断。由于缺乏特征性症状,97.3%的病例在术中被诊断。接受鞘膜壁局部切除术的患者中,35.7%出现局部肿瘤复发,而阴囊睾丸切除术和腹股沟睾丸切除术后分别为10.5%和11.5%。因此,根治性睾丸切除术应作为一线治疗方法。患者的中位生存期为23个月,复发患者降至14个月。总体复发率(局部和播散性)为52.5%。超过60%的复发发生在随访的前2年内。在一些播散性间皮瘤病例中,给予了辅助化疗或放疗。虽然关于辅助治疗的报道有限,但放疗似乎比化疗更有效。然而,37.9%的患者死于疾病进展。预后参数评估显示,单变量分析中患者年龄与生存有显著相关性(P<0.01),年轻患者预后较好,原发性播散性疾病患者病程较差(P<0.05)。关于生存的预后参数多变量Cox回归模型未得出具有统计学意义的结果。
睾丸鞘膜恶性间皮瘤很少见,但所有年龄组都应考虑到这种可能性。单变量分析确定患者年龄和原发性播散性疾病的存在是与生存相关的预后参数。由于这种疾病的侵袭性和肿瘤复发风险强烈建议进行根治性睾丸切除术并密切随访。